Alexion’s managed access programs address the need of patients with serious or life-threatening disease or conditions through access to our medicines.
Commitment to Patients
Alexion is committed to serving people affected by rare diseases through the discovery, development and access of life-changing medicines. Our goal is to bring safe and effective medicines to as many patients as possible by conducting rigorous clinical trials and obtaining marketing approval by regulatory authorities around the world.
Our work is marked by a commitment to the highest standards of preclinical and clinical research, and an acute sense of urgency. As such, we prioritize access to our investigational medicines through participation in a clinical trial.
We recognize there are circumstances where patients with serious or life-threatening diseases have exhausted other comparable or satisfactory alternative therapeutic options and may not be eligible or able to participate in a clinical trial. In such circumstances, subject to the criteria set forth below and country specific regulations, patients may be eligible for managed access to Alexion’s medicines.
All requests for access to medicine must be unsolicited and made by the patient’s treating physician. Each request will be assessed on a case-by-case basis. Alexion will consider granting managed access to its medicines when the following criteria are met:
For all managed access inquiries, please contact the Alexion Managed Access Team.